Therapeutics and COVID-19
Home/
Teams/
Health Care Readiness/
Clinical management of COVID-19/
Therapeutics and COVID-19
WHO develops the most up-to-date clinical practice guidelines for the use of therapeutics for patients with COVID-19 based on ongoing assessment of new evidence generated by the international medical research community and first responders.
Guidelines and resources on this page include:  

 
Learn more
Clinical management of COVID-19
Oxygen Access Scale Up
Oxygen Resource Page
COVID-19 Clinical Data Platform  
Therapeutics and COVID-19 Guideline Development
The WHO steering committee meets regularly to review new evidence for therapeutics and prioritize when a new guideline update will be triggered.

WHO Guideline Development Group (GDG) is made up of an expert panel of global experts, frontline providers and patient partners developing transparent and trustworthy quality COVID-19 clinical practice guidelines. –
Biographies of experts: WHO Guideline Development Group Living Guidelines for COVID-19.

The GDG convenes regularly to prepare for and review evidence summaries from international clinical trials with the support of an expert team of methodologists; and then develops clinical practice recommendations for the use of therapeutics to treat patients with COVID-19 of any disease severity. Guidelines undergo peer review by a further set of clinicians and the Guideline Review Committee prior to publication.  

Rapid adaptation and implementation of WHO-recommended therapeutics into the COVID-19 clinical care pathways is essential at national and local levels to impact patient outcomes. 

Current list of therapeutics under review by the GDG with tentative timelines for the publication of recommendations and upcoming meetings: 
WHO handbook for guideline development
R&D Blueprint and COVID-19
WHO COVID-19 Solidarity Therapeutics Trial
 
Publications
All →
The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform, and is updated regularly as new evidence emerges.
This eighth version of the WHO living guideline now contains 14 recommendations, including three new recommendations regarding Janus kinase (JAK) inhibitors and sotrovimab. No further updates to the previous existing recommendations were made in this latest version.
 

14 January 2022
Therapeutics and COVID-19: living guideline
Download
Read More
The bmj: A living WHO guideline on drugs for COVID-19
MagicApp: Drugs to prevent COVID-19, WHO Living guideline
The WHO Therapeutics and COVID-19: living guideline currently includes a:
Other COVID-19 therapeutics that are currently under consideration by WHO include molnupiravir, fluvoxamine, nirmatrelvir/ritonavir, colchicine and anticoagulants. This guideline will be updated if/when sufficient new evidence warrants this. 
Guidelines regarding the use of drugs to prevent (rather than treat) COVID-19 are included in a separate document, WHO Living guideline: Drugs to prevent COVID-19, that can be accessed via an online platform and in pdf format (or click ‘PDF’ in top right corner of online platform).
Guidelines regarding the clinical management of COVID-19 patients are included in a further document, COVID-19 Clinical management: Living guideline, that can be accessed via an online platform and in pdf format (or click ‘PDF’ in top right corner of online platform).
To view previous (now outdated) versions of this guideline, please see the links below:
COVID-19 Therapeutic tools and resources for health care workers 
15 November 2021
Clinical Training Module - Introduction to therapeutics and COVID-19
Corticosteroids
15 November 2021
Clinical Training Module - Corticosteroids and COVID-19
Corticosteroids Meta Analysis
Association Between Administration of...
JAMA. 2020;324(13):1330-1341
Drug treatments for covid-19: living systematic...
BMJ 2020; 370
IL6 Receptor Blockers
15 November 2021
Clinical Training Module - IL6 Receptor Blockers and COVID-19
IL6 Receptor Blockers Meta Analysis
Association Between Administration of IL-6...
JAMA. 2021;326(6):499-518
Drug treatments for covid-19: living systematic...
BMJ 2020; 370
Casirivimab and Imdevimab – Neutralising monoclonal antibodies (nMAb)
23 November 2021
Clinical Training Module - Casirivimab and Imdevimab and COVID-19
Casirivimab and Imdevimab – Neutralising nMAb Meta Analysis
Drug treatments for covid-19: living systematic...
BMJ 2020; 370
Posters/clinical tools for administration of therapeutics
11 January 2022
Poster: Preparation of intravenous casirivimab and imdevimab for COVID-19
11 January 2022
Poster: Safety and monitoring in patients receiving casirivimab and imdevimab for...
11 January 2022
Poster: Preparation and administration of subcutaneous casirivimab and imdevimab for...
11 January 2022
Poster: Monoclonal antibodies casirivimab and imdevimab for COVID-19
11 January 2022
Poster: Infusion of Intravenous casirivimab and imdevimab for COVID-19
Resources for patients, caregivers and familiesAll →
Coronavirus disease (COVID-19): Dexamethasone
Coronavirus disease (COVID-19): Hydroxychloroquine
Coronavirus disease (COVID-19): Solidarity Trial and hydroxychloroquine
Regions
Policies
About us
Subscribe to our newsletters
Privacy Legal Notice   
Preventing sexual exploitation
© 2022 WHO
HomeTeamsHealth Care ReadinessClinical management of COVID-19